表紙
市場調查報告書

真性多血症:開發中產品分析

Polycythemia Vera - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 192784
出版日期 內容資訊 英文 129 Pages
訂單完成後即時交付
價格
真性多血症:開發中產品分析 Polycythemia Vera - Pipeline Review, H1 2020
出版日期: 2020年02月28日內容資訊: 英文 129 Pages
簡介

真性多血症(PV)是幹細胞異常的一種疾病,特徵是全身增生性(panhyperplastic)、惡性、腫瘤性骨髓疾病。主要症狀有疼痛和頭痛、暈眩、倦怠感、過度發汗等。此外也有風險隨年齡增加而增大的趨勢。主要治療藥有甲醇烷基化藥等。

本報告提供全球各國治療真性多血症(真性多血症)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

真性多血症概要

治療藥的開發

  • 真性多血症開發中產品:概要
  • 真性多血症開發中產品:比較分析

各企業開發中的真性多血症治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

真性多血症治療藥:開發中的產品一覽(各企業)

真性多血症開發治療藥的企業

  • ANP Technologies, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Galena Biopharma, Inc.
  • Gilead Sciences, Inc.
  • Italfarmaco S.p.A.
  • Karus Therapeutics Limited
  • miRagen Therapeutics, Inc.
  • Nerviano Medical Sciences S.r.l.
  • Novartis AG
  • PharmaEssentia Corporation
  • Teva Pharmaceutical Industries Ltd.

真性多血症:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

真性多血症治療藥:暫停開發的產品

真性多血症治療藥:中止開發的產品

真性多血症相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12010IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycythemia Vera - Pipeline Review, H1 2020, provides an overview of the Polycythemia Vera (Oncology) pipeline landscape.

Polycythemia Vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant and neoplastic marrow disorder. Symptoms include itchiness, headache, dizziness, weakness and excessive sweating. The risk of polycythemia vera increases with age. Treatment includes alkylating agents.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycythemia Vera - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Polycythemia Vera (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycythemia Vera (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 9, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Polycythemia Vera (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Polycythemia Vera (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Polycythemia Vera (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Polycythemia Vera (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Polycythemia Vera (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Polycythemia Vera (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Polycythemia Vera (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Polycythemia Vera (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

TABLE OF CONTENTS

Introduction

  • Polycythemia Vera - Overview
  • Polycythemia Vera - Therapeutics Development
  • Polycythemia Vera - Therapeutics Assessment
  • Polycythemia Vera - Companies Involved in Therapeutics Development
  • Polycythemia Vera - Drug Profiles
  • Polycythemia Vera - Dormant Projects
  • Polycythemia Vera - Discontinued Products
  • Polycythemia Vera - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Polycythemia Vera, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Polycythemia Vera - Pipeline by AbbVie Inc, H1 2020
  • Polycythemia Vera - Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Polycythemia Vera - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
  • Polycythemia Vera - Pipeline by Gilead Sciences Inc, H1 2020
  • Polycythemia Vera - Pipeline by Imago BioSciences Inc, H1 2020
  • Polycythemia Vera - Dormant Projects, H1 2020
  • Polycythemia Vera - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Polycythemia Vera, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020